SBH
KNSA icon

Segall Bryant & Hamill’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Segall Bryant & Hamill’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,026
Closed -$675K – 612
2024
Q3 		$675K Buy
+27,026
New +$658K 0.01% 534

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Segall Bryant & Hamill's KNSA Position: Q4 2024 in Review

Segall Bryant & Hamill sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 27,026 shares — an estimated $675K sold.

Segall Bryant & Hamill first reported a position in KNSA in Q3 2024 and held it in 1 quarter. The position peaked at $675K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Segall Bryant & Hamill reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Segall Bryant & Hamill sold 27,026 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $675K.
  • Segall Bryant & Hamill first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Segall Bryant & Hamill's Kiniksa Pharmaceuticals position peaked at $675K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Segall Bryant & Hamill's 13F filing for Q4 2024, filed 11 Feb 2025.